Maplelane Capital’s Astera Labs ALAB Stock Holding History

Maplelane Capital’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-101,000	Closed	-$5.29M	–	150
2024 Q3	$5.29M	Buy	+101,000	New	+$4.74M	0.3%	62

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

Atreides Management Boston, Massachusetts $14.3B AUM 116.01% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Maplelane Capital's ALAB Position: Q4 2024 in Review

Maplelane Capital sold out of Astera Labs (ALAB) in Q4 2024, closing a stake of 101,000 shares — an estimated $5.29M sold.

Maplelane Capital first reported a position in ALAB in Q3 2024 and held it in 1 quarter. The position peaked at $5.29M in Q3 2024. 421 funds tracked by Wall St. Rank hold ALAB as of Q4 2024.

Maplelane Capital reported no remaining Astera Labs position as of Q4 2024 after selling out during the quarter.
Maplelane Capital sold 101,000 Astera Labs shares in Q4 2024, an estimated $5.29M.
Maplelane Capital first reported a position in Astera Labs in Q3 2024 and held it in 1 quarter.
Maplelane Capital's Astera Labs position peaked at $5.29M in Q3 2024.
421 funds tracked by Wall St. Rank held Astera Labs as of Q4 2024.

Based on Maplelane Capital's 13F filing for Q4 2024, filed 14 Feb 2025.